Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

Official Title

An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Details

Keywords

Locally Advanced or Metastatic Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Lasofoxifene, Fulvestrant, ER+/HER2, ESR1 mutation, Breast Neoplasms

Eligibility

Locations

  • UCSF Cancer Center
    San Francisco California 94115 United States
  • City of Hope Comprehensive Cancer
    Duarte California 91010 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Sermonix Pharmaceuticals Inc.
ID
NCT03781063
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated